Drugs / AGSAVI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05503953 | Oct 2022 → Jun 2025 | essential hypertension | Ahn-Gook Pharmaceuticals Co.,Ltd | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGSAVI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05503953 ↗ |